Premier Fund Managers LTD Veracyte, Inc. Transaction History

Premier Fund Managers LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$21.0 - $29.1 $36,603 - $50,721	-1,743 Reduced 14.07%	10,641 $231,000
Q3 2023 Nov 08, 2023	SELL	$22.33 - $29.92 $464,151 - $621,917	-20,786 Reduced 62.67%	12,384 $284,000
Q2 2023 Aug 03, 2023	SELL	$20.96 - $26.99 $230,685 - $297,051	-11,006 Reduced 24.91%	33,170 $859,000
Q4 2022 Feb 09, 2023	BUY	$15.31 - $29.94 $652,910 - $1.28 Million	42,646 Added 2787.32%	44,176 $1.06 Million
Q4 2022 Feb 08, 2023	SELL	$15.31 - $29.94 $652,910 - $1.28 Million	-42,646 Reduced 96.54%	1,530 $434,000
Q1 2022 May 10, 2022	BUY	$21.94 - $42.51 $969,221 - $1.88 Million	44,176 New	44,176 $1.27 Million
Q4 2021 Feb 14, 2022	SELL	$36.09 - $53.79 $2.04 Million - $3.05 Million	-56,623 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$32.94 - $56.62 $1.91 Million - $3.28 Million	-57,877 Reduced 50.55%	56,623 $2.34 Million
Q3 2020 Nov 13, 2020	BUY	$26.73 - $35.67 $283,338 - $378,102	10,600 Added 10.2%	114,500 $3.75 Million
Q2 2020 Aug 13, 2020	BUY	$19.49 - $28.11 $2.03 Million - $2.92 Million	103,900 New	103,900 $2.69 Million

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Premier Fund Managers LTD, based on Form 13F filings with the SEC.

Stay updated on Premier Fund Managers LTD with notifications on news.